Cargando…
Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries
Medicine treatments for bone-related diseases such as osteoporosis, bone metastasis, osteomyelitis, and osteolysis are often limited by insufficient drug concentration at the lesion sites owing to the low perfusion of bone tissue. A carrier that can deliver multiple bone destruction site-targeting d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296467/ https://www.ncbi.nlm.nih.gov/pubmed/35854057 http://dx.doi.org/10.1038/s41598-022-15941-w |
_version_ | 1784750280300036096 |
---|---|
author | Pan, Yixiao Wang, Jiahao Jiang, Zichao Guo, Qi Zhang, Zhen Li, Jingyi Hu, Yihe Wang, Long |
author_facet | Pan, Yixiao Wang, Jiahao Jiang, Zichao Guo, Qi Zhang, Zhen Li, Jingyi Hu, Yihe Wang, Long |
author_sort | Pan, Yixiao |
collection | PubMed |
description | Medicine treatments for bone-related diseases such as osteoporosis, bone metastasis, osteomyelitis, and osteolysis are often limited by insufficient drug concentration at the lesion sites owing to the low perfusion of bone tissue. A carrier that can deliver multiple bone destruction site-targeting drugs is required to address this limitation. Here, we reported a novel bone-targeting nano-drug delivery platform formed by the integration of zoledronate (ZOL) and zeolitic imidazolate framework-8 (ZIF-8) nanoparticles. The ZOL mixed zeolitic imidazolate framework (ZZF) nanoparticles were synthesized in water at room temperature (25 °C), where many biomacromolecules could maintain their activity. This allowed the ZZF nanoparticles to adapt the encapsulation ability and pH response release property from ZIF-8 and the excellent bone targeting performance of ZOL simultaneously. Considering the ease of preparation and biomacromolecule-friendly drug delivery of this nano platform, it may be useful in treating bone-related diseases. |
format | Online Article Text |
id | pubmed-9296467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92964672022-07-21 Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries Pan, Yixiao Wang, Jiahao Jiang, Zichao Guo, Qi Zhang, Zhen Li, Jingyi Hu, Yihe Wang, Long Sci Rep Article Medicine treatments for bone-related diseases such as osteoporosis, bone metastasis, osteomyelitis, and osteolysis are often limited by insufficient drug concentration at the lesion sites owing to the low perfusion of bone tissue. A carrier that can deliver multiple bone destruction site-targeting drugs is required to address this limitation. Here, we reported a novel bone-targeting nano-drug delivery platform formed by the integration of zoledronate (ZOL) and zeolitic imidazolate framework-8 (ZIF-8) nanoparticles. The ZOL mixed zeolitic imidazolate framework (ZZF) nanoparticles were synthesized in water at room temperature (25 °C), where many biomacromolecules could maintain their activity. This allowed the ZZF nanoparticles to adapt the encapsulation ability and pH response release property from ZIF-8 and the excellent bone targeting performance of ZOL simultaneously. Considering the ease of preparation and biomacromolecule-friendly drug delivery of this nano platform, it may be useful in treating bone-related diseases. Nature Publishing Group UK 2022-07-19 /pmc/articles/PMC9296467/ /pubmed/35854057 http://dx.doi.org/10.1038/s41598-022-15941-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pan, Yixiao Wang, Jiahao Jiang, Zichao Guo, Qi Zhang, Zhen Li, Jingyi Hu, Yihe Wang, Long Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
title | Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
title_full | Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
title_fullStr | Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
title_full_unstemmed | Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
title_short | Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
title_sort | zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296467/ https://www.ncbi.nlm.nih.gov/pubmed/35854057 http://dx.doi.org/10.1038/s41598-022-15941-w |
work_keys_str_mv | AT panyixiao zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT wangjiahao zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT jiangzichao zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT guoqi zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT zhangzhen zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT lijingyi zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT huyihe zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries AT wanglong zoledronatecombinedmetalorganicframeworksforbonetargetinganddrugsdeliveries |